<p xmlns="http://www.w3.org/1999/xhtml">
Quanterix Corporation (NASDAQ:<a class="ticker" href="https...

<p xmlns="http://www.w3.org/1999/xhtml">
Quanterix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/QTRX">QTRX</a>), a company fueling scientific discovery through ultra-sensitive biomarker detection (the "Company"), today announced that the Company's 2026 annual meeting of shareholders (the "Annual Meeting") will be held virtually, by means of remote communication, on Tuesday, June 9, 2026 at 10:00 am Eastern Time. Stockholders of record of the Company's common stock as of the close of business on April 14, 2026 will be entitled to vote at the Annual Meeting. Additional information regarding the Annual Meeting will be provided in the Company's proxy statement.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Because the date of the Annual Meeting has been advanced by more than thirty (30) days from the anniversary date of the Company's 2025 annual meeting, the Company has set a new deadline for the receipt of shareholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), for inclusion in the Company's proxy materials for the Annual Meeting. In order to be considered timely, such proposals must be received by the Company's Secretary no later than April 6, 2026. Any proposal submitted after the above deadline will not be considered timely and will be excluded from the Company's proxy materials.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Additionally, in accordance with the advance notice provisions set forth in the Company's Bylaws, in order for a shareholder proposal to be submitted outside of Rule 14a-8 of the Exchange Act or a director nomination submitted by a shareholder to be considered timely, it must be received by the Company's Secretary not later than April 6, 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Quanterix</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,300 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup>, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,439 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue -- advancing precision medicine from discovery to diagnostics. Learn more at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.quanterix.com&amp;esheet=54469068&amp;newsitemid=20260327100682&amp;lan=en-US&amp;anchor=www.quanterix.com&amp;index=1&amp;md5=334c659f078c6ab9ad3461a44e28d34e" shape="rect">www.quanterix.com</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260327100682r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260327100682/en/" rel="nofollow">https://www.businesswire.com/news/home/20260327100682/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Investor Relations Contact: 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Joshua Young
<br xmlns="http://www.w3.org/1999/xhtml"></br>(508) 846-3327
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:ir@quanterix.com" shape="rect">ir@quanterix.com</a>

</p>

QTRX

Quanterix Corporation Announces Date of 2026 Annual Meeting

Quanterix Sets Date for Virtual 2026 Annual Shareholder Meeting

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;p xmlns=&quot;http://www.w3.org/1999/xhtml&quot;&gt;
Quanterix Corporation (NASDAQ:&lt;a class=&quot;ticker&quot; href=&quot;https...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Quanterix has scheduled its 2026 annual meeting for June 9, 2026, with proposal submissions due by April 6, 2026. The Company&#039;s advanced biomarker detection technology and recent acquisition of Akoya Biosciences position it well in precision medicine, suggesting growth potential and possible increased shareholder interest.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Quanterix announces its 2026 annual meeting date as June 9, 2026.</li><li>Shareholders must submit proposals by April 6, 2026, for inclusion.</li><li>Company&#039;s technology enhances biomarker detection in diagnostics and drug development.</li><li>Quanterix acquired Akoya Biosciences, boosting its biomarker detection capabilities.</li><li>Company has 6,300 peer-reviewed publications validating its technology.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Akoya Biosciences (AKYA)</strong>: Quanterix’s acquisition enhances their biomarker detection offerings.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The company is categorized under Corporate Developments, as the announcement of the annual meeting and proposal deadlines can influence shareholder decisions and enhance corporate governance.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Shareholder proposal deadline may lead to significant investor engagement.</li><li>Acquisition of Akoya may drive future revenue growth and market interest.</li><li>Technological advancements could attract new partnerships and customers.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>2026 annual meeting is set for June 9, 2026.</li><li>Proposals must be submitted by April 6, 2026.</li><li>Quanterix&#039;s technology enables biomarker detection at low concentrations.</li><li>Company has over 6,300 peer-reviewed publications.</li><li>Acquired Akoya Biosciences in 2025, enhancing its technology portfolio.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>QTRX is positioned for growth due to its technology and recent acquisition; buy in the near term.</p>
  </section>
</section>


<article>
    <h2>Quanterix Corporation Schedules Virtual 2026 Annual Meeting</h2>
    <p>Quanterix Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/quote/QTRX">QTRX</a>), a pioneering company in ultra-sensitive biomarker detection, has announced that its <strong>2026 Annual Meeting of Shareholders</strong> will take place virtually on <strong>June 9, 2026</strong>, at <strong>10:00 AM Eastern Time</strong>. This decision enables stockholders to participate remotely. Shareholders who own common stock as of the close of business on <strong>April 14, 2026</strong> will have the right to vote during the meeting. Further details about the meeting will be included in the company's upcoming <em>proxy statement</em>.</p>

    <section>
        <h3>Shareholder Proposal Deadlines</h3>
        <p>The date for the Annual Meeting has been moved more than 30 days from the anniversary of the previous year's meeting. As a result, Quanterix has established a new deadline for shareholder proposals under Rule 14a-8 of the <em>Securities Exchange Act of 1934</em>. Proposals must be submitted to the Company’s Secretary by <strong>April 6, 2026</strong> to be considered timely. Proposals received after this date will not be included in the proxy materials.</p>
        
        <p>Additionally, to meet the requirements outlined in the Company’s Bylaws, any shareholder proposal or director nomination submitted outside of Rule 14a-8 must also be received by <strong>April 6, 2026</strong>, to be considered timely for the upcoming Annual Meeting.</p>
    </section>

    <section>
        <h3>About Quanterix Corporation</h3>
        <p>Quanterix is at the forefront of biomarker detection and has been a trusted partner in disease research, diagnostics, and drug development for nearly 20 years. The Company's proprietary <strong>Simoa<sup>&reg;</sup></strong> technology provides unparalleled sensitivity, allowing researchers to detect biomarkers in blood and bodily fluids at lower concentrations than conventional methods. The company has supported approximately <strong>6,300 peer-reviewed publications</strong>, asserting its importance in the scientific community.</p>

        <p>In 2025, Quanterix expanded its capabilities by acquiring <strong>Akoya Biosciences</strong>, known as The Spatial Biology Company<sup>&reg;</sup>. This acquisition introduced advanced multiplexed tissue imaging, significantly enhancing Quanterix's portfolio, which now includes <strong>1,439 installed instruments</strong>. Together, they are working towards a more integrated approach to precision medicine, bridging discoveries in blood and tissue.</p>

        <p>For more detailed information about Quanterix and its innovative technology, please visit <a href="https://www.quanterix.com" rel="nofollow">www.quanterix.com</a>.</p>
    </section>

    <section>
        <h3>Contact Information</h3>
        <p><strong>Investor Relations:</strong><br>
        Joshua Young<br>
        Phone: (508) 846-3327<br>
        Email: <a href="mailto:ir@quanterix.com" rel="nofollow">ir@quanterix.com</a></p>
    </section>
</article>

Quanterix has scheduled its 2026 annual meeting for June 9, 2026, with proposal submissions due by April 6, 2026. The Company's advanced biomarker detection technology and recent acquisition of Akoya Biosciences position it well in precision medicine, suggesting growth potential and possible increased shareholder interest.

Quanterix Corporation Announces Date of 2026 Annual Meeting

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News